Measurements of anti-tumor reactivity vary depending on the cancer (melanoma, uveal melanoma, lung, bladder), the method for determining tumor infiltrating lymphocyte (TIL) reactivity (IFNγ production, CD137/4-1BB and CD134/OX40 expression), and the types of cells that are tested [26,27,28,29]. The gene discussed is TNFRSF9; the disease is cancer.